MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral arteries in detail, but standardized vessel measurement often requires extensive manual analysis. This workload can slow large studies and increase variation between users. To streamline these measurements and improve consistency, researchers have developed ArteryX, a software tool for more automated brain artery analysis.

The ArteryX software toolbox was developed by researchers at University of Rochester Medicine (Rochester, NY, USA). It analyzes three-dimensional time-of-flight magnetic resonance angiography, an MRI technique used to visualize blood vessels in the brain. The tool measures vessel length, radius, volume, surface area, branching, tortuosity, and fractional dimensionality. These features allow researchers to assess the structure and organization of the brain’s arterial network.

The technology was described in a study published in Magnetic Resonance in Medicine. Researchers compared ArteryX with iCafe, an existing toolbox for cerebral artery analysis. ArteryX required approximately 10–15 minutes of processing and user interaction. A trained user working with iCafe required roughly 1.5 hours.

The researchers evaluated ArteryX using data from a cohort of people with and without CSVD from a recently completed URochester Medicine study. In that analysis, ArteryX detected several vascular differences between groups that iCafe did not identify. These included changes in smaller vessels. The findings suggest that detailed arterial measurements could support research into potential biomarkers of cerebrovascular disease.

The technology is currently an academic research tool, and a version is freely available for academic use. The team is also exploring ways to combine brain artery structure with blood-flow information. Before clinical use, ArteryX would require extensive validation across different MRI scanners and patient populations. Researchers would also need evidence that its measurements improve risk assessment or disease monitoring.

“We are working to make ArteryX more automated, faster and more comprehensive. Ultimately, our goal is to make quantitative brain-vessel analysis more accessible, reproducible and useful for research and, eventually, clinical care,” said Nasir Uddin, Ph.D., project lead.

“Developing ArteryX has been an exciting opportunity to translate advanced MRI image analysis into a practical tool for the neuroscience community. We hope the platform will enable larger, more reproducible studies and help researchers discover new imaging biomarkers for cerebrovascular disease,” said Abrar Faiyaz, Ph.D., postdoctoral research associate in Uddin’s lab.

Related Links
University of Rochester Medicine